Head to Head Survey: iSpecimen (NASDAQ:ISPC) & Repligen (NASDAQ:RGEN)

iSpecimen (NASDAQ:ISPC – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Valuation and Earnings

This table compares iSpecimen and Repligen”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iSpecimen $1.93 million 0.79 -$10.49 million ($56.44) -0.01
Repligen $738.26 million 14.09 $48.89 million ($0.21) -775.14

Repligen has higher revenue and earnings than iSpecimen. Repligen is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

13.6% of iSpecimen shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

iSpecimen has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.

Profitability

This table compares iSpecimen and Repligen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iSpecimen -2,445.40% -524.39% -140.42%
Repligen -1.47% 5.49% 3.93%

Analyst Recommendations

This is a summary of current ratings and target prices for iSpecimen and Repligen, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iSpecimen 1 0 0 0 1.00
Repligen 1 3 12 2 2.83

Repligen has a consensus target price of $178.57, suggesting a potential upside of 9.70%. Given Repligen’s stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than iSpecimen.

Summary

Repligen beats iSpecimen on 12 of the 14 factors compared between the two stocks.

About iSpecimen

(Get Free Report)

iSpecimen, Inc. operates an online marketplace that connects life-science researchers with hospitals, laboratories, biobanks and other providers of human biospecimens. Its platform is designed to help researchers find and request samples for medical and scientific research. Through its iSpecimen Marketplace, the company facilitates access to materials such as blood, tissue and other human specimens, along with associated data when available. It also supports the coordination of specimen sourcing and fulfillment between research organizations and providers.

About Repligen

(Get Free Report)

Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.

Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.